ANAPLASTIC LARGE CELL LYMPHOMA (ALCL) (ALK-1 NEGATIVE)

Clinical trials for ANAPLASTIC LARGE CELL LYMPHOMA (ALCL) (ALK-1 NEGATIVE) explained in plain language.

Never miss a new study

Get alerted when new ANAPLASTIC LARGE CELL LYMPHOMA (ALCL) (ALK-1 NEGATIVE) trials appear

Sign up with your email to follow new studies for ANAPLASTIC LARGE CELL LYMPHOMA (ALCL) (ALK-1 NEGATIVE), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet recruiting 1

New hope for seniors with rare blood cancer: gentler chemo shows promise

Disease control Not yet recruiting

This study tests a new chemotherapy combination called CAOP for elderly patients (65+) with a rare type of lymphoma called peripheral T-cell lymphoma (PTCL). The goal is to see if replacing a standard drug with a less heart-toxic one can still control the cancer while being safer…

Matched conditions: ANAPLASTIC LARGE CELL LYMPHOMA (ALCL) (ALK-1 NEGATIVE)

Phase: PHASE2 • Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Disease control

Last updated May 26, 2026 10:46 UTC

ANAPLASTIC LARGE CELL LYMPHOMA (ALCL) (ALK-1 NEGATIVE)

Get alerted when new ANAPLASTIC LARGE CELL LYMPHOMA (ALCL) (ALK-1 NEGATIVE) trials appear

New hope for seniors with rare blood cancer: gentler chemo shows promise